HALIX is a biopharmaceutical contract development and manufacturing organization (CDMO) based in the Netherlands, specialising in mammalian expression systems for the production of immune-stimulating viruses and antibodies. With a state-of-the-art facility spanning 6,700 sq.m., HALIX employs scalable single-use technologies to deliver services for the development and GMP manufacturing of drug substances (DS) and drug products (DP). The organisation has secured several contracts for the production of oncolytic immunotherapies and vaccines, including the large-scale commercial manufacture of AstraZeneca's COVID-19 vaccine.

Services include:
- Contract Development and Manufacturing (CDMO)
- Regulatory Services
- Protein and Peptide
- Cell and Gene Therapy
- Injectables
- Clinical Dose
- Packaging
- Clinical Packaging

HALIX is committed to providing high-quality biopharmaceutical manufacturing solutions, ensuring compliance and innovation in the rapidly evolving pharmaceutical industry. For more information, please visit halix.nl.